• Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
Band 89

Tumor Antigenicity and Approaches to Tumor Immunotherapy An Outline

Fr. 72.90

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

18.10.2011

Verlag

Springer Berlin

Seitenzahl

86

Maße (L/B/H)

24.4/17/0.6 cm

Gewicht

189 g

Auflage

1980

Sprache

Englisch

ISBN

978-3-642-67499-0

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

18.10.2011

Verlag

Springer Berlin

Seitenzahl

86

Maße (L/B/H)

24.4/17/0.6 cm

Gewicht

189 g

Auflage

1980

Sprache

Englisch

ISBN

978-3-642-67499-0

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
  • 1 Tumor-Associated Antigenicity and Host Responsiveness: Basic Questions and Considerations.- 2 Tumor Etiology and Antigenicity.- 2.1 Tumors Known to be Induced by Viruses.- 2.2 Tumors Known to be Induced by Chemical Agents and by Other Carcinogenic Stimuli.- 2.3 “Spontaneous” Tumors, with No Obvious Viral Etiology (Animal und Human).- 3 Approaches to Immunotherapy.- 3.1 Active “Nonspecific Immunogherapy” with Immunomodulating Agents.- 3.1.1 Loci of Immunomodulator Influence on Antitumor Immune Responses.- 3.1.1.1 Nonspecific Potentiation of Specific Responsiveness to Tumor associated Antigens.- 3.1.1.2 Nonspecific “Spillover” of Potentiated Specific Responsiveness to TAAs.- 3.1.1.3 Nonspecific Potentiation of Specific Immunological Reactions Against Antigens Other than TAAs.- 3.1.1.4 Antigenic Cross-reactivity Between Microbial Immunomodulators and Tumor Cells.- 3.1.1.5 Direct Nonspecific Activation of Immunocytes and Its Nonspecific Consequences.- 3.1.1.6 Nonimmunological Loci of Action of Substances with Immunomodulator Properties.- 3.1.1.7 General Comments.- 3.1.2 Nonliving Immunomodulators of Microbial Origin.- 3.1.3 Intralesional and Regional Versus Distal Immunotherapeutic Administration of Immunomodulators.- 3.1.4 Combined Modalities of Treatment Including Intervention with Nonspecific Immunomodulators.- 3.1.5 Possible Advantages Inherent in the Nonspecific Approach to Tumor Immunotherapy.- 3.2 Active Specific Immunization with Tumor Cell Antigens.- 3.2.1 General Considerations.- 3.2.2 Modification of Tumor Cell Antigens.- 3.2.3 Other Possible Means of Specific Immunization.- 3.3 Passive and Adoptive Immunological Intervention.- 3.3.1 General Considerations.- 3.3.2 In Vitro Generation of Cytotoxic Effector Cells Against Tumors.- 3.3.3 Potentiation of the In Vitro Generation of Cytotoxic Effector Cells.- 3.3.4 In Vitro Production of Antibodies and Its Potentiation.- 3.3.5 Possibilities and Problems of Clinical Application.- 4 Concluding Remarks.- 4.1 Immune Surveillance and Immunological Intervention: Hypothesis and Empiricism.- 4.2 Key Aspects of the Approaches to Tumor Immunotherapy.- 4.3 Goals and Expectations.- 4.4 Experimental Perspectives.- 4.5 Immunological Capacity, Immunological Monitoring, and Susceptibility to Neoplastic Disease.- 4.6 Immunological and Nonimmunological Resistance to Progressive Neoplasia.- 4.7 Coda.- 5 Notes added in Press.- Acknowledgements.- References.